Rezdiffra (Resmetirom) and Prednisone Interaction: What Patients and Clinicians Need to Know

What Is the Resmetirom, Prednisone Interaction?

Resmetirom and prednisone interact through two distinct mechanisms operating simultaneously. The pharmacodynamic conflict is the more clinically consequential concern: prednisone promotes hepatic steatosis, hyperglycemia, and dyslipidemia, while resmetirom was designed specifically to reverse those same metabolic abnormalities in MASH. The pharmacokinetic component involves shared hepatic processing pathways that could nudge drug exposures in either direction, though the magnitude is unlikely to be dramatic in most patients.

Clinicians prescribing prednisone to a patient already on Rezdiffra should think of the combination as temporarily pressing the accelerator and the brake at the same time. The interaction is not a hard contraindication, but it demands structured monitoring and a commitment to the shortest effective glucocorticoid course.

Resmetirom: Mechanism of Action

Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist. THR-β receptors are expressed predominantly in the liver, and activation drives a package of metabolic changes: reduced hepatic triglyceride synthesis, increased mitochondrial fatty acid beta-oxidation, downregulation of lipogenic transcription factors including SREBP-1c, and a modest lowering of LDL cholesterol via upregulation of hepatic LDL receptors. [1]

In the key MAESTRO-NASH trial (N=966), patients receiving resmetirom 100 mg once daily for 52 weeks showed MASH resolution without worsening fibrosis in 25.9% of cases versus 14.2% on placebo (P<0.001). [2] Fibrosis improvement of at least one stage occurred in 24.2% of the 100-mg group versus 14.2% of placebo recipients. The drug was approved by the FDA on March 14, 2024, specifically on the basis of these histologic endpoints. [3]

Prednisone: Mechanism of Action and Hepatic Effects

Prednisone is a prodrug converted by 11-beta-hydroxysteroid dehydrogenase in the liver to its active form, prednisolone. Glucocorticoids bind to cytosolic glucocorticoid receptors, translocate to the nucleus, and broadly upregulate gluconeogenic enzymes (PEPCK, G6Pase) while simultaneously promoting lipolysis in peripheral fat, releasing free fatty acids that flow to the liver for re-esterification into triglycerides. [4]

This hepatic fat-loading effect is dose- and duration-dependent. Even modest doses of 10 to 20 mg/day prednisone for 4 to 6 weeks have been associated with measurable increases in hepatic steatosis on MRI-PDFF in metabolically vulnerable patients. [5] For a patient being treated for MASH, this represents a direct conflict with the entire goal of resmetirom therapy.

Pharmacokinetic Interaction: CYP3A4 and OATP Pathways

How Resmetirom Is Metabolized

Resmetirom is a substrate of CYP3A4 for oxidative metabolism and of the hepatic uptake transporters OATP1B1 and OATP1B3 for hepatocellular entry. [1] According to the FDA-approved Rezdiffra prescribing information, co-administration with strong CYP3A4 inhibitors (such as itraconazole) increased resmetirom AUC by approximately 2-fold. Strong CYP3A4 inducers are expected to reduce resmetirom exposure, although the label does not provide a quantified fold-change for induction. [3]

Prednisone and prednisolone are themselves CYP3A4 substrates. At therapeutic doses, they are not classified as clinically meaningful CYP3A4 inducers or inhibitors in the way that rifampin or ketoconazole are. Their net effect on resmetirom plasma concentrations is expected to be minimal. Clinicians do not need to adjust resmetirom's dose on the basis of CYP3A4 pharmacokinetics when prescribing a standard prednisone course.

OATP1B1 Transporter Considerations

OATP1B1 is responsible for hepatic uptake of a wide range of drugs, including statins, and resmetirom relies on it for delivery into the hepatocyte, the site of action. [1] Glucocorticoids are not established OATP1B1 inhibitors at typical clinical concentrations, so significant transporter-level pharmacokinetic interaction is not expected. SLCO1B1 genotype (encoding OATP1B1) is already known to influence resmetirom exposure, and patients with known reduced-function SLCO1B1 variants may warrant additional attention. [3]

Protein Binding and Volume of Distribution

Both drugs are highly protein-bound: resmetirom binds to albumin and thyroid-binding globulin analogs, and prednisolone binds primarily to transcortin (CBG) and albumin. Protein-binding displacement interactions are theoretically possible but rarely produce clinically significant changes in free drug concentration for drugs with wide therapeutic indices. No protein-binding displacement interaction of clinical significance has been reported in the literature for this pair to date.

Pharmacodynamic Interaction: The Core Clinical Concern

The pharmacodynamic conflict between resmetirom and prednisone can be organized into three overlapping domains, each with its own monitoring parameter and management response.

Domain 1: Hepatic Steatosis and MASH Progression

Resmetirom's entire value proposition in MASH is to reduce hepatic fat and resolve steatohepatitis. Prednisone opposes this by driving free fatty acid flux into the liver and upregulating lipogenic pathways via insulin resistance-mediated hyperinsulinemia. A systematic review of glucocorticoid-associated metabolic liver disease found that cumulative prednisolone exposure above 3,000 mg (roughly 100 days at 30 mg/day) was independently associated with a 2.3-fold increased risk of fatty liver progression in pre-existing metabolic liver disease. [5]

For patients on resmetirom, every day of prednisone therapy at doses above 10 mg/day risks partially negating histologic gains that took months to achieve. The prescribing physician should ask whether the glucocorticoid indication can be addressed with a topical, inhaled, or intra-articular route instead, thereby minimizing systemic hepatic exposure.

Domain 2: Glucose Metabolism and Diabetes Risk

Approximately 40 to 50% of patients with MASH already have type 2 diabetes or prediabetes. [6] Prednisone causes steroid-induced hyperglycemia through multiple mechanisms: peripheral insulin resistance, impaired pancreatic beta-cell function at high doses, and increased hepatic gluconeogenesis. Blood glucose elevations are often greatest in the afternoon and evening with morning prednisone dosing, a pattern that can be missed by routine fasting glucose checks alone.

In the MAESTRO-NASH population, mean baseline HbA1c was 6.9%, placing many participants in the prediabetic or early diabetic range. [2] Adding prednisone to resmetirom therapy in this population risks tipping patients into overt hyperglycemia requiring new antidiabetic medications. A 2-hour postprandial glucose check or a continuous glucose monitor (CGM) for the duration of prednisone therapy may be more informative than fasting glucose alone.

Domain 3: Lipid Metabolism

Resmetirom produces clinically meaningful LDL reductions: the MAESTRO-NASH 52-week data showed a mean LDL-C reduction of approximately 13.6% from baseline with resmetirom 100 mg. [2] Prednisone may modestly raise triglycerides and LDL-C through glucocorticoid-mediated VLDL overproduction and impaired lipoprotein lipase activity. The net effect in a patient on both drugs is partial blunting of resmetirom's lipid benefit.

Fasting lipid panels should be ordered at the start of prednisone therapy and again at completion. Clinicians should not interpret a worsening lipid panel during prednisone treatment as evidence of resmetirom failure without first accounting for the glucocorticoid contribution.

Bone Health: A Secondary Overlap

Both MASH with advanced fibrosis and chronic glucocorticoid therapy independently increase fracture risk. Glucocorticoid-induced osteoporosis (GIOP) begins within 3 to 6 months of therapy at doses above 7.5 mg/day prednisone equivalent, as noted in the American College of Rheumatology's 2022 GIOP guidelines. [7] Resmetirom does not appear to have direct skeletal effects, but patients receiving long-term glucocorticoids alongside resmetirom therapy should be evaluated for baseline DEXA scan and calcium/vitamin D supplementation per GIOP guidelines.

Immune Suppression and Infection Risk in MASH

Patients with advanced MASH (F2, F3 fibrosis) may already have altered immune function related to portal hypertension and gut dysbiosis. Prednisone adds systemic immunosuppression on top of this background. Serious infections, including bacterial pneumonia and opportunistic fungal infections, are more common in patients with hepatic fibrosis receiving glucocorticoids compared with fibrosis-free patients on equivalent doses. [8]

Resmetirom does not cause immunosuppression. Its safety profile in MAESTRO-NASH showed no excess serious infections versus placebo. [2] The infection risk in this combination is attributable to prednisone and the underlying liver disease, not to resmetirom itself. Clinicians should update vaccinations (pneumococcal, influenza, hepatitis A, hepatitis B) before initiating prolonged prednisone therapy in MASH patients.

Severity Classification of This Drug Interaction

Drug interaction databases classify the resmetirom, prednisone combination as a moderate interaction, meaning the combination is not contraindicated but requires active clinical management. This classification reflects:

• Pharmacodynamic antagonism of meaningful clinical magnitude (hepatic steatosis, glucose, lipids)
• Absence of a severe pharmacokinetic interaction requiring dose adjustment
• A reversible conflict that resolves when prednisone is tapered and stopped

The FDA prescribing information for Rezdiffra does not list prednisone or systemic glucocorticoids as contraindicated co-medications. [3] The label does instruct caution with CYP3A4 interactions and notes that the drug's hepatic effects could be influenced by co-medications that alter liver fat metabolism. Prednisone fits the latter category.

Monitoring Protocol During Overlapping Therapy

Laboratory Parameters

Patients taking resmetirom who require a prednisone course should have the following tests checked at baseline (before prednisone starts) and then at 4-week intervals while on prednisone:

• Fasting glucose and 2-hour postprandial glucose (or CGM if available)
• HbA1c (every 8 to 12 weeks, given the 3-month integration window)
• Fasting lipid panel (LDL-C, triglycerides, HDL-C)
• Hepatic function panel (ALT, AST, alkaline phosphatase, bilirubin, albumin)
• Body weight (weekly, as fluid retention may mask fat changes)

Clinical Symptoms to Monitor

Patients should report new or worsening polyuria, polydipsia, blurred vision, ankle swelling, abdominal distension, easy bruising, or jaundice. Each of these may signal steroid-induced metabolic derangement or hepatic decompensation in the setting of underlying MASH.

Prednisone Course Duration Targets

When prednisone is medically necessary, aim for the minimum effective dose for the minimum necessary duration. For most non-autoimmune inflammatory conditions, courses under 14 days at doses below 20 mg/day carry substantially lower risk of clinically significant hepatic fat worsening than courses exceeding 4 weeks. If prednisone is required long-term (for autoimmune hepatitis, lupus, or inflammatory bowel disease, for example), a formal multidisciplinary discussion involving gastroenterology or hepatology alongside the prescribing specialist is warranted.

Patient Counseling Points

Patients taking Rezdiffra who are prescribed prednisone by another provider should receive clear messaging on three points.

First, the prednisone is not expected to cause a dangerous or life-threatening reaction with resmetirom, so there is no reason to stop resmetirom without physician instruction.

Second, the steroid may temporarily blunt the benefit they are getting from Rezdiffra on their liver, blood sugar, and cholesterol. This is a reason to take prednisone for the shortest time their condition allows, not a reason to panic.

Third, they should tell every prescriber they see that they are on Rezdiffra, because MASH and its metabolic associations affect how many other medications behave in the liver.

The American Association for the Study of Liver Diseases (AASLD) states in its 2023 MASH clinical practice guidance that "patients with MASH and concurrent systemic inflammatory conditions requiring glucocorticoids should be counseled that steroid therapy may accelerate hepatic fat deposition and should have hepatic function monitored at least quarterly." [9]

Special Populations

Patients With Type 2 Diabetes

Diabetic patients in MASH are at the highest risk for steroid-induced glycemic crises. In this subgroup, communication with an endocrinologist or primary care physician to pre-emptively adjust antidiabetic therapy (typically with basal insulin or GLP-1 receptor agonist dose titration) before starting prednisone at doses of 20 mg/day or above is a reasonable clinical step.

Patients on Statins or Fibrates

Many MASH patients also take statins or fenofibrate for dyslipidemia. Statins are OATP1B1 substrates, and resmetirom competes for the same transporter. The Rezdiffra label flags this interaction separately. Adding prednisone to a resmetirom-plus-statin regimen introduces a third variable that may affect statin exposure, though clinical reports of significant statin toxicity from this three-way interaction are not yet published.

Patients With Cirrhosis

The Rezdiffra approval is limited to fibrosis stages F2, F3 (moderate-to-advanced fibrosis, not yet cirrhosis). Patients with compensated cirrhosis (F4) were excluded from MAESTRO-NASH. [2] If prednisone is given to a patient with cirrhosis for any indication, the risk of hepatic decompensation is substantially higher, and the resmetirom, prednisone combination in this context has no trial data to anchor clinical decision-making.

Summary of Interaction Management

The resmetirom, prednisone interaction is best managed through four concrete actions:

1. Confirm that systemic prednisone is truly necessary, ruling out topical, inhaled, or intra-articular alternatives.
2. Set a defined prednisone taper schedule before the first dose, targeting the shortest course consistent with the indication.
3. Establish a laboratory monitoring schedule (glucose, lipid panel, hepatic function) at baseline and every 4 weeks during therapy.
4. Reassess resmetirom efficacy at the next scheduled hepatic evaluation (typically FibroScan or liver biopsy at 52 weeks per MAESTRO protocol) with the awareness that a glucocorticoid course may have temporarily shifted biomarkers.

Rezdiffra's FDA prescribing information specifies that dose adjustments are not required based solely on mild-to-moderate CYP3A4 pharmacokinetic interactions. [3] The 80-mg or 100-mg once-daily dose (chosen based on patient weight per label guidance) should be continued without interruption unless hepatic function deteriorates to Child-Pugh B or C, which is a labeled contraindication regardless of co-medications.